Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Associations between clinical signs and pathological findings in toxicity testing
Karolinska Institute, Sweden.
Stockholm University, Sweden.
Uppsala University, Sweden.
RISE Research Institutes of Sweden, Bioeconomy and Health, Chemical Process and Pharmaceutical Development.ORCID iD: 0000-0002-6699-5413
Show others and affiliations
2021 (English)In: Altex, ISSN 1868-596X, E-ISSN 1868-8551, Vol. 38, no 2, p. 198-214Article in journal (Refereed) Published
Abstract [en]

Animal testing for toxicity assessment of chemicals and pharmaceuticals must take the 3R principles into consideration. During toxicity testing in vivo, clinical signs are used to monitor animal welfare and to inform about potential toxicity. This study investigated possible associations between clinical signs, body weight change and histopathological findings observed after necropsy. It was hypothesized that clinical signs and body weight loss observed during experiments could be used as early markers of organ toxicity. This represents a potential for Refinement in terms of improved study management and decrease of pain and distress experienced during animal experiments. To this end, data from three sequential toxicity studies in rats were analyzed using the multivariate partial least squares (PLS) regression method. Associations with correct prediction over 80% were found between the occurrence of mild to severe clinical signs and histopathological findings in the thymus, testes, epididymides and bone marrow. Piloerection, eyes half shut and slightly decreased motor activity showed the strongest associations to the pathological findings. A 5% body weight loss was found to be a strong empirical predictor of pathological findings but could also be predicted accurately by clinical signs. Thus, we suggest using mild clinical signs and a 5% body weight loss as toxicity markers, and as a non-invasive surveillance tool to monitor research animal's welfare and toxicity testing. These clinical signs may also enable Reduced animal use due to their informative potential to support scientific decisions regarding drug candidate selection, dose setting, study design and toxicity assessment.

Place, publisher, year, edition, pages
2021. Vol. 38, no 2, p. 198-214
Keywords [en]
Refinement, pharmaceutical development, toxicity testing, clinical signs, animal welfare
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:ri:diva-50947DOI: 10.14573/altex.2003311PubMedID: 33118607OAI: oai:DiVA.org:ri-50947DiVA, id: diva2:1506269
Available from: 2020-12-02 Created: 2020-12-02 Last updated: 2021-07-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Platzack, Björn

Search in DiVA

By author/editor
Platzack, Björn
By organisation
Chemical Process and Pharmaceutical Development
In the same journal
Altex
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf